Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

Fig. 2

a Kaplan-Meier estimates of overall survival in mice engrafted with ibrutinib resistant TCL1 splenocytes and treated with vehicle, ibrutinib (30 mg/kg daily in drinking water), SNX-5422 (50 mg/kg 3 days/week) or the combination. The log-rank p-value between the combination SNX-5422 + ibrutinib vs either vehicle or ibrutinib was calculated (combo vs vehicle, p = 0.007; combo vs ibrutinib, p = 0.002). b Mice spleens were weighed at early removal criteria and compared between treatment groups (combo vs vehicle, p < 0.001; combo vs ibrutinib, p < 0.001; vehicle vs ibrutinib, p = 0.035). c Weekly peripheral blood disease burden evaluated by %CD19+CD5+ of CD45+ cells of mice described in Figure 3A and that are alive at each time point. d Histopathology performed on spleen, lymph node, liver, lung and bone marrow reveals reduced leukemic infiltration in the liver, lungs, and marrow of SNX-5422 and SNX-5422 + ibrutinib treated groups

Back to article page